Chugai Pharmaceutical (OTCMKTS:CHGCY) Posts Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) released its quarterly earnings results on Thursday. The company reported $0.18 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.30% and a net margin of 33.85%.

Chugai Pharmaceutical Stock Performance

Chugai Pharmaceutical stock traded down $0.30 during trading hours on Thursday, hitting $20.33. The company had a trading volume of 89,914 shares, compared to its average volume of 189,677. The firm has a market cap of $66.91 billion, a P/E ratio of 26.06 and a beta of 0.81. The company has a 50-day moving average price of $21.62 and a two-hundred day moving average price of $22.43. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $26.00.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.